What is Collegium's latest dividend and current dividend yield?

Did Collegium beat or miss consensus estimates last quarter?

What were the key takeaways from Collegium's earnings call?

What were the key takeaways from Collegium’s earnings call?

What is Collegium's gross profit margin?

What does Collegium do and what are its main business segments?

What is the revenue and EPS growth rate for Collegium year over year?

What factors drove the changes in Collegium's revenue and profit?

- **Record Financial Performance**: 2025 net revenue up 24% to $780.6 million, driven by Jornay PM (48% growth) and a resilient pain portfolio.
- **Jornay PM Momentum**: 2026 revenue guidance of $190-200 million reflects 31% YoY growth, supported by 180 sales reps and targeted marketing.
- **Capital Strength**: $386 million in cash, syndicated credit facility reduces debt costs, and 2026 EBITDA expected to remain stable at $455-475 million.
- **Strategic Focus**: Expanding Jornay PM, maximizing pain portfolio durability, and disciplined capital deployment for long-term value.

**【CEO Summary Section】**
- **2025 Financial Milestones**: Full-year net revenue grew 24% to $780.6 million, with adjusted EBITDA up 15% to $460.5 million. Jornay PM revenue surged 48% to $148.9 million, while the pain portfolio contributed $631.7 million, up 6% year-over-year.
- **Strategic Priorities**: Focused on Jornay PM growth (20% prescription increase), pain portfolio durability, and capital deployment. Jornay prescriptions reached 760,000 in 2025, with 29,000 prescribers, up 21% YoY.
- **Capital Deployment**: Closed a $980 million syndicated credit facility to reduce debt costs and enhance flexibility for business development. Repurchased $25 million in shares in 2025.

**【CFO Financial Commentary】**
- **2025 Financial Highlights**: GAAP net income of $62.9 million, operating cash flow of $329.3 million, and ending cash of $386.7 million. Jornay PM gross to net ratio stabilized at 64%, supporting 2026 guidance of $190-200 million in revenue.
- **2026 Guidance**: Total product revenue expected to grow 4% to $805-825 million, driven by Jornay PM (31% YoY growth) and stable pain portfolio contributions. Adjusted EBITDA projected at $455-475 million.
- **Debt Management**: Achieved net leverage below 1x, with interest savings from the new credit facility.

**【Q&A Key Highlights】**
- **Jornay PM Growth Drivers**: Expanded sales force (180 reps) and marketing investments, with Q4 prescriptions up 16% YoY. 2026 guidance assumes stable gross to net ratio and continued prescriber engagement.
- **Competitive Landscape**: No material threats from competitors; Jornay's unique evening dosing remains a key differentiator.
- **Pain Portfolio Resilience**: Belbuca and Xtampza maintain strong prescriber bases (over 20,000 each) and promotional sensitivity, supported by efficient commercial infrastructure.
- **Capital Allocation Strategy**: Prioritizes business development in neuropsychiatry, pediatrics, and rare diseases with long exclusivity. Share buybacks ($150 million remaining) and debt repayment balance risk and return.

Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript

- **Q3 Standout**: 31% revenue growth to $209.4M, Jornay PM at $41.8M (+20% scripts YoY), and pain portfolio resilience.
- **Strategic Focus**: Jornay expansion, 2025 guidance raise to $775-785M, and 24% YoY growth.
- **Financial Strength**: $31.5M net income, 1.2x leverage, $285.9M cash. Gross to net mid-60%, supporting 2026 momentum.
- **Key Drivers**: Jornay's 46% 2025 target, pain portfolio durability, and disciplined capital deployment.

**【CEO Summary Section】**
- **Record Q3 Performance**: Total revenue of $209.4 million, up 31% year-over-year, driven by Jornay PM's 20% prescription growth and pain portfolio expansion.
- **Jornay PM Momentum**: Generated $41.8 million in net revenue, with 14% weekly script increase during back-to-school season. Adult segment grew 29% YoY, targeting 21,000 prescribers.
- **Pain Portfolio Resilience**: Pain products contributed $167.6 million, up 11% YoY, with Belbuca and Xtampza maintaining #1 differentiation in ER markets.
- **Capital Deployment**: Repaid $16.1 million debt, ending Q3 with $285.9 million cash. Raised 2025 guidance to $775-785 million revenue, 24% YoY growth.

**【CFO Financial Commentary】**
- **Financial Health**: GAAP net income $31.5 million (238% YoY growth), adjusted EBITDA $133 million (27% YoY). Gross to net improved to mid-60%, offsetting sales force expansion costs.
- **Leverage Strategy**: Net debt/EBITDA at 1.2x, targeting <1x by year-end. Share buybacks ($25M returned) and debt repayment support long-term growth.

**【Q&A Highlights】**
- **Script Growth Dynamics**: Jornay's 20% YoY growth driven by 3,800 new prescribers and 62% gross to net. Q4 2025 and 2026 Outlook: Expect Q4 gross to net stabilization, 2026 focus on Jornay's 46% revenue target and pain portfolio durability.
- **M&A and Strategy**: Active in BD, prioritizing commercial assets with call point synergies. Cautious on R&D risk, focusing on near-commercial opportunities.
- **Execution Confidence**: Team execution and capital deployment poised for 2026 acceleration, balancing growth and financial discipline.

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 29% YoY growth to $188M, driven by Jornay PM (23% prescriptions YoY) and pain portfolio (7% YoY). Jornay revenue hit $32.6M, adult prescriptions up 33% YoY.
- **Jornay Market Share**: 23% of branded methylphenol products, and the company's products. The company's products,2025年，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素，长期因素。长期因素，长期因素，长期因素，长期因素，长期因素。

**【CEO Summary】**
- **Revenue Growth**: Total revenue grew 29% YoY to $188 million, driven by Jornay PM (23% YoY prescriptions) and pain portfolio (7% YoY). Jornay revenue reached $32.6 million, while pain portfolio generated $155.4 million.
- **Jornay PM Momentum**: Market share of long-acting branded methylphenidate expanded to 23%, up 7.6 percentage points YoY. Adult prescriptions grew 33% YoY, reflecting demand for morning efficacy.
- **Capital Deployment**: Completed $25M share repurchase, repaid $16.1M debt, and authorized $150M share repurchase program. Cash position stands at $222M.
- **Guidance Update**: Raised 2025 revenue guidance to $745-$760M (19% YoY growth) and adjusted EBITDA to $440-$455M (12% YoY growth). Jornay revenue expected to reach $140-$145M, up 42% YoY.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $12M, Non-GAAP adjusted EBITDA of $105.1M (9% YoY growth). Operating expenses rose 69% YoY to $73.3M due to Jornay commercialization costs.
- **Cash Flow**: Generated $72.4M in operating cash flow, with $72.4M in free cash flow. Debt-to-EBITDA leverage reduced to 1.4x, targeting <1x by year-end.
- **Leverage Strategy**: Balancing business development, share repurchases, and debt repayment to maximize shareholder value.

**【Commercial Highlights】**
- **Jornay PM Expansion**: Sales force expanded to 180 reps, targeting 21,000 prescribers. 2,700 new targets wrote prescriptions in Q2. Back-to-school season campaigns focus on caregiver awareness.
- **Pain Portfolio Resilience**: Belbuca, Xtampza ER, and Nucynta ER each achieved YoY growth, supported by abuse-deterrent technologies and strong brand differentiation.
- **Generic Competition Defense**: No generics expected to launch against pain portfolio products in the near term due to supply chain constraints and regulatory hurdles.

**【Q&A Highlights】**
- **Jornay Prescriber Growth**: Prescriber base reached 26,000 (23% YoY), with 2,700 new targets writing prescriptions in Q2.
- **Adult ADHD Market**: Jornay captures 20% of adult prescriptions, targeting 30%+ share through morning efficacy messaging.
- **Pain Portfolio Durability**: Xtampza ER ranked #1 ER oxycodone medicine in differentiation, with exclusivity into 2027.
- **M&A Strategy**: Open to BD opportunities in pain/CNS, prioritizing commercial-stage assets that leverage existing infrastructure.


Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

- **Jornay PM Growth**: 24% YoY prescriptions, $28.5M Q1 revenue, 20.3% market share in long-acting methylphenidate.
- **Sales Force Expansion**: 180 reps targeting 21,000 prescribers, with full impact in 2026.
- **Financial Strength**: $197.8M cash, $55.4M Q1 cash flow, and 2025 guidance for 18% revenue growth.
- **Strategic Moves**: $25M ASR, debt repayment, and potential $300M+ BD deals.
- **Market Dynamics**: 5-6% ADHD market growth, generics driving branded share gains.

**【CEO Summary Section】**
- **Strategic Priorities**: Growth of Jornay PM, maximizing pain portfolio, and capital deployment for shareholder value.
- **Jornay PM Performance**: 24% YoY prescription growth, $28.5M net revenue in Q1, with full-year guidance of >$135M (34% YoY growth).
- **Financial Strength**: $197.8M cash on hand, $55.4M Q1 cash flow, and $25M ASR program authorization.
- **Leadership Updates**: Expansion of sales force to 180 reps, new executive hires, and Board refreshment.

**【Commercial Update by Scott Dreyer】**
- **Jornay Market Share**: 20.3% in long-acting methylphenidate market (up 6.4% YoY), driven by 25,000+ prescribers.
- **Sales Force Expansion**: 55 new reps added, targeting 21,000 prescribers, with full impact expected in 2026.
- **Pain Portfolio Resilience**: 3% YoY revenue growth despite market headwinds, with Xtampza and Belbuca maintaining differentiation.

**【CFO Financial Highlights】**
- **Q1 2025 Results**: $177.8M net product revenue (+23% YoY), $95.2M adjusted EBITDA (+3% YoY).
- **2025 Guidance**: $735-750M net product revenue, $435-450M adjusted EBITDA, and <1x net leverage by year-end.
- **Capital Deployment**: $16.1M debt repayment in Q1, with $48.4M additional repayments planned for 2025.

**【Q&A Key Takeaways】**
- **Seasonality**: Jornay scripts may slow in Q2 due to summer break, but back-to-school season (August-December) expected to drive growth.
- **Sales Force Strategy**: Focus on expanded reach (21,000 targets) and frequency, with 6-month lag to impact.
- **BD Appetite**: Open to transactions up to $300M+ if strategic fit, with preference for commercial-stage assets.
- **Market Growth**: ADHD market growing 5-6% YoY, with generics driving branded share gains.

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

- **11% Revenue Growth**: 2024 total revenue reached $631.4 million, driven by 31% Journee prescription growth.
- **$135M Journee Target**: 2025 net revenue expected to exceed $135 million, supported by 180-rep sales force expansion.
- **Extended Exclusivity**: Nucynta exclusivity extended to July 2027, safeguarding $176.5 million franchise.
- **Financial Strength**: 2024 adjusted EBITDA $401.2 million; 2025 guidance for $435-450 million with <1x net debt by year-end.

**【CEO Summary Section】**
- **2024 Financial Highlights**: Total revenue grew 11% to $631.4 million, driven by 31% growth in Journee prescriptions (636,200 in 2024). Adjusted EBITDA increased 9% to $401.2 million.
- **Strategic Acquisitions**: Acquired Ironshore Therapeutics, with Journee net revenue of $100.7 million in 2024, projected to exceed $135 million in 2025 (+34%).
- **2025 Priorities**: Expand Journee sales force to 180 reps (from 125), invest in digital marketing, and extend Nucynta exclusivity to July 2027.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Net product revenue $181.9 million (+22% YoY), with BELBUCA ($55.2M, +12% YoY) and Xtampza ER ($51.5M, +6% YoY) leading growth.
- **Cost Management**: GAAP operating expenses $207.4 million (+30% YoY) due to Journee integration, but adjusted EBITDA margin improved to 63.5%.
- **2025 Guidance**: Net product revenue $735-750 million, adjusted EBITDA $435-450 million, with $60M share buybacks completed in 2024.

**【Q&A Key Takeaways】**
- **Sales Force Expansion**: Targeting 60% of long-acting ADHD market with 180 reps, covering 23,000 prescribers.
- **Generic Risks**: No competitor has the regulatory/legal/manufacturing capacity to launch generics for Nucynta or BELBUCA until 2027+.
- **NOPAIN Act Impact**: No effect on retail-based chronic pain portfolio.
- **M&A Strategy**: Focused on neuropsychiatry/CNS and rare disease assets with near-term revenue potential.

Actual												0.8882	0.9467	1.0274	0.93	0.9806	0.8565	0.8746	-0.4995	1.0786	1.1828	1.1	1.09	1.32	1.26	1.34	1.58	1.45	1.62	1.61	1.77	1.49	1.68	2.25	2.04
Forecast												0.6614	0.8586	0.8986	0.9657	1.0013	0.9629	0.96	1.0417	0.895	1.44	1.3817	1.092	1.3329	1.218	1.2182	1.3784	1.4703	1.4851	1.5915	1.5377	1.4325	1.6167	1.86	2.1292
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+34.29%	+10.26%	+14.33%	-3.70%	-2.07%	-11.05%	-8.90%	-147.95%	+20.51%	-17.86%	-20.39%	-0.18%	-0.97%	+3.45%	+10.00%	+14.63%	-1.38%	+9.08%	+1.16%	+15.11%	+4.01%	+3.92%	+20.97%	-4.19%

COLL

COLL fundamentals

COLL Q4 2025 Earnings

Earnings Call

You can ask Aime

COLL

COLL fundamentals

COLL Q4 2025 Earnings

Earnings Call

COLL Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

COLL Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

COLL Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

COLL Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

COLL Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime